ClinicalTrials.gg
RecruitingNCT06844136ChemoINtelUpdated Feb 28, 2025

ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients

An observational study in Ovarian Cancer, sponsored by Pierian Biosciences. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Pierian Biosciences · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 293 studies in Ovarian Neoplasms with a site in United Kingdom — 54 open to participants now, 85 under way, 25 of them phase 3. Ovarian Neoplasms · United Kingdom.

Planned enrollment
26th of 35
100 · median 235
Started
2023
with 10 others
Observational
35 of 293
8 open now
Primary completion
2026-07
later than 20 of 84 live
Registered
275th of 293
by date

Among the 293 studies in Ovarian Neoplasms with a site in United Kingdom, this one is the 26th largest by planned enrollment of the 35 observational ones that give a count, is one of 11 that started in 2023, is one of 35 observational ones, reaches primary completion later than 20 of the 84 other live ones, and was the 275th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

54 of the 293 studies in Ovarian Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies in Ovarian Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a prospective, non-randomized, observational, clinical development study. Pierian Biosciences is utilizing ChemoINTEL and ImmunoINTEL assay measurements in human tumour cells from patients with advanced stage epithelial ovarian cancer (EOC) to develop a mathematical algorithm which will be able to predict a patient's tumour's sensitivity to specific chemotherapy drugs. The study involves using a sample of tumour biopsy taken during standard of care surgery, with a matched blood sample if possible. Medical history, pathology information and information on chemotherapy for up to 6 cycles will be requested. The information will then be used to developed an algorithm to predict tumour sensitivity to treatment.

Read the detailed description

The justification for this study is to provide evidence based predictive scoring of available cytotoxic drug based on the patient's own tumour response characteristics to guide the physician's therapeutic selections and enable a personalized treatment plan. This study will generate a predictive algorithm using individual patient tumour ChemoINTEL and ImmunoINTEL assay response metrics paired with the patient's clinical response data. Subsequent Clinical Validation and Clinical Utility Studies will be conducted to provide further evidence for utilization of personalized predictive response scoring of available therapeutics enabling section of personalized treatment regiments based on each patient's unique tumour as an improvement over guideline driven approaches.

Cancer treatments and selection of cytotoxic drugs used in different situations continues to be guideline driven. These selections are generally based on treatment protocols developed as a result of large, population-based, prospective, randomized, multicenter, well-controlled phase 3 studies that analyze treatment outcomes (progression-free survival [PFS] and overall survival [OS]) as a function of treatment received by patient cohorts. This approach was necessitated by the stark reality that no "predictive" or "treatment-directing" diagnostic technologies were available, a circumstance that, to an overwhelming degree, remains unaltered. Treatment "guidelines" are utilized by most oncologists globally as they recommend treatment algorithms and options based on data with the highest levels of evidence. Several treatment guidelines are available globally such as those produced by the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), and European Society of Medical Oncology (ESMO). These guidelines provide evidence-based recommendations to guide physicians and outline appropriate methods of treatment and care. The guidelines often address specific clinical situations (disease oriented) on the use of approved medical products, procedures, or tests (modality oriented).

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Ovarian cancer diagnosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Screening Criteria:

  • Females ≥18 years of age
  • Patient must sign an Form
  • Patient is suspected to have one of the following

    • advanced stage Epithelial Ovarian Cancer (EOC)
    • advanced stage Primary Peritoneal Carcinomatosis
    • advanced stage Fallopian Tube Carcinoma

Inclusion criteria

Inclusion Criteria:

  • Females ≥18 years of age
  • Diagnosis by pathology of one of either advanced stage EOC, Primary Peritoneal Carcinomatosis, or Fallopian Tube Carcinoma

    • Newly diagnosed
    • Recurrent
  • Patient provided an evaluable tumor or peritoneal fluid specimen prior to initiating chemotherapy for ChemoINTEL assay analysis
  • Patient received at least 3 cycles of standard of care chemotherapy for advanced stage EOC with single agent or combination of drugs summarised as below, following OR surgical resection

    • Carboplatin
    • Cisplatin
    • Cyclophosphamide-4HC active metabolite
    • Docetaxel
    • Doxorubicin
    • Etoposide
    • Fluorouracil
    • Gemcitabine
    • Ifosfamide-4HI active metabolite
    • Irinotecan
    • Oxaliplatin
    • Paclitaxel
    • Pemetrexed
    • Topotecan
    • Vinorelbine
    • Bevacizumab (Avastin)
  • Patients will have an appropriate evaluation after their third cycle and sixth cycle of SOC chemotherapy to document response by either 2009 v1.1, CA-125 KELIM Scoring, and/or circulating tumor DNA longitudinal monitoring
  • Patient signed Informed Consent Form

Exclusion criteria

Exclusion Criteria:

  • Patient has not signed an ICF to participate in a clinical investigation
  • Patient has a cancer other than advanced stage EOC
  • Patient did NOT receive SOC chemotherapy, single agents or combination treatment from the indicated list above.
  • Patients did NOT have sufficient viable cells recovered from either a fresh tumor dissociation or peritoneal fluid specimen collected prior to initiating chemotherapy available for the minimum ChemoINTEL assay analysis of Carboplatin, Cisplatin, Docetaxel, and Paclitaxel test conditions
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group 1

    De Novo (no prior cytotoxic therapy) receiving primary cytoreductive surgery and adjuvant chemotherapy

    Other: No intervention

  • Group 2

    De Novo (no prior cytotoxic therapy) receiving neoadjuvant chemotherapy and interval cytoreductive surgery followed by additional chemotherapy

    Other: No intervention

  • Group 3

    Recurrent (one or more prior lines of previous cytotoxic therapy) receiving next line of chemotherapy

    Other: No intervention

Interventions

  • OtherNo intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. Prediction Algorithm

    To develop a prediction algorithm that uses input from the ChemoINTEL and ImmunoINTEL assay metric results and provides an accurate prediction of a patient's cancer's sensitivity to specific chemotherapeutic agents by assessing the patient's response based on either RECIST criteria (v 1.1, 2009), CA-125 KELIM Score, and/or circulating tumor DNA changes to the administered chemotherapy following three cycles of SOC chemotherapy.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Liverpool Women's NHS Foundation Trust
    Liverpool, Merseyside L8 7SS, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Plan to disseminate the findings and publish the findings, all data will be anonymised

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Jul 2026, 32 months after the start.

Of 52 industry-sponsored observational studies under Ovarian Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 71. This study's planned 32 months is below that.

Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 25, 2025
StartActual
Nov 22, 2023
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2027
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06844136
Lead sponsor
Pierian Biosciences
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Nov 22, 2023
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Feb 28, 2025

Study contacts

Norman Purvis, PhD
Contact
npurvis@pierianbio.com
+44 (0)333 034 1690
Maria Maguire, PhD
Contact
maria.maguiire2@nhs.net
07824609720
Robert Henry
study director · Pierian Biosciences Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion